Long non-coding RNAs (lncRNAs) have emerged as potent regulators of cardiac disease; however, the role of lncRNA in cardiac fibrosis remains partially understood.
| INTRODUC TI ON
, and display a mesenchymal phenotype). 3 In the fibrotic heart of patients with chronic kidney disease, around 17% of fibroblasts are derived from EndMT. 4 Furthermore,
EndMT has been reported to contribute to cardiac fibrosis in endothelin-1 knockout diabetic mice 5 and isoproterenol (Iso)-induced heart failure rats. 6, 7 The patients' and animal models' evidence suggests that EndMT plays a vital role in cardiac remodelling.
Prostaglandin E2 receptor 4 (EP4), also known as Ptger4, is a prostaglandin E2 (PGE2) receptor subtype, 8 which is reportedly involved in the development of various cardiovascular diseases such as myocardial hypertrophy, myocardial ischaemia-reperfusion injury, myocarditis, heart failure and atherosclerosis. 9, 10 Reportedly, EP4 silencing increases the collagen content and aggravates cardiac fibrosis 11 ; in contrast, activation of EP4 by ONO-0260164 reduces collagen deposition. 12 In some studies, EndMT was inhibited by PGE2 stimulation 13 and then rescued by selective EP4 antagonists AH-23848. 14 A recent study reported that the EP4 agonist, L-902688, also suppressed EndMT and then attenuated right ventricular cardiac fibrosis in pulmonary arterial hypertension rats.
15
These studies highlight that the EP4 activation reduces cardiac fibrosis by inhibiting EndMT.
Long non-coding RNAs (lncRNAs) are a class of non-coding RNA with a length larger than 200 nucleotides; some of them participated in the pathogenesis of heart development, 16 hypertrophy, 17 heart failure, 18 myocardial infarction 19 and cardiac fibrosis. 20 Recently, lncRNA MALAT1 modulated TGF-β1-induced
EndMT by the down-regulation of miR-145 in neointimal hyperplasia. 21 The overexpression of lncRNA uc.77 and 2700086A05Rik
induced epithelial-mesenchymal transition (EMT, a process similar to EndMT) in human lung epithelial cells and might facilitate the development of pulmonary fibrosis. 22 These data indicate that lncRNAs might mediate EndMT contribution to cardiac fibrosis.
However, whether some lncRNAs target EP4 receptor to regulate
EndMT remains unclear.
This study aims to perform the RNA sequencing in a rat model of heart fibrosis and identify a cardiac endothelial-enriched lncRNAlnc000908, which is markedly up-regulated in rats with cardiac fibrosis. The lnc000908 gene located in the upstream of the EP4 receptor gene and the overexpression of lnc000908 down-regulated the EP4 expression. By lentivirus-delivery shRNA to the knockdown of lnc000908 in the heart enhanced the cardiac pump function and inhibited cardiac fibrosis by increasing EP4 to lower EndMT. Similarly, the controls were administered an equal volume of saline.
| MATERIAL S AND ME THODS

| Cardiac fibrosis model
We harvested hearts that were stored in RNA later™ Stabilization Solution (Ambion) for lncRNA analysis.
| RNA sequencing
We performed RNA sequencing on fibrotic and control hearts (3 samples each group) with service from Novogene per the manufacturer's standard protocols. Briefly, 3 μg of RNA per sample was used as input material for the RNA sample preparations. In addition, sequencing libraries were generated using the rRNA-depleted RNA by NEB Next ® Ultra™ Directional RNA Library Prep Kit from Illumina ® (NEB). After cluster generation, the libraries were sequenced on an Illumina HiSeq 2500 platform, and 125-bp paired-end reads were generated. Transcripts with P adjust < 0.05 were assigned as differentially expressed. Furthermore, the Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis were performed to ascertain the role of the closest genes to which lncRNAs are preferentially located.
| Lentiviral vector construction and animals' in vivo study
In this study, we used lentivirus (Hanbio Inc) to conduct the loss-offunction experiment. Lnc000908 was amplified by PCR (polymerase chain reaction) and cloned into a backbone plasmid (lenti-sh908).
The negative control plasmid (lenti-ctrl) was lack of lnc000908 sequence. Lentivirus (2 × 10 9 pfu/rat) was administered in one into the tail vein before Iso infusion. The lenti-ctrl infused group served as negative controls. After 21 days, rats were killed with an overdose of pentobarbital (100 mg/kg, one dose intraperitoneally).
The hearts were harvested for future analysis. We randomly di- 
| Echocardiograph
We performed transthoracic echocardiography using a Sonos 5500 ultrasound machine (Phillips) with a 12-MHz probe on days 
| Enzyme-linked immunosorbent assay for the collagen content
Heart tissues were weighed and sliced into pieces on ice, then ho- 
| Quantitative real-time PCR
We extracted the total RNA with TRIzol (Invitrogen), and 2 μg of RNA was used for the cDNA synthesis by reverse transcription.
The real-time PCR was performed on the LightCycler ® 96 RealTime PCR System (Roche) using the SYBR green method. The PCR conditions comprised a denaturation step at 95°C for 30 seconds, then 40 cycles of amplification at 95°C for 10 seconds and 60°C for 10 seconds. Next, lncRNA expression levels were normalized to GAPDH. The relative expression of the lncRNAs was assessed using the 2 −∆∆ CT method. All primer sequences used were listed as follows: lnc000908, forward 5′-AGGGAGGAGGGTGGTAGT-3′ and reverse 5′-GGTTTGTTTGTGAGGTGTTT-3′; EP4, forward 5′-TCGCGC AAGGAGCAGAAGGACAC-3′ and reverse 5′-GACGGTGGCGAGAAT GAGGAAGGA-3′.
| Western blot analysis
We extracted proteins from heart tissues and cultured cells using lysis buffer and centrifuged at 10 400 g for 10 minutes at 4°C.
Protein concentrations were quantified by the BCA method (PC0020; Solarbio Life Sciences). Next, 80 μg samples were added on the gel for SDS-PAGE and then transferred to PVDF membranes.
After blocking with 5% non-fat milk for 1 hour at room temperature, membranes were incubated with primary antibodies overnight at 4°C and then with horseradish-conjugated secondary antibodies.
The protein expression was quantified by the Bio-Rad Gel Image
Analysis System (Bio-Rad) and Image-Pro Plus (Media Cybernetics, Inc). The total protein levels were normalized to GAPDH. The primary antibodies used were as follows: anti-CD31, ab28364; anti-VEcadherin, ab33168; anti-α-SMA, ab5694; anti-Vimentin, ab92547, all from Abcam, 1:500; anti-EP4, 24985-1-AP, Proteintech, 1:500; and rabbit anti-GAPDH.
| Cell culture
We purchased primary rat cardiac microvascular endothelial cells (CMECs), cardiac fibroblasts (CFs), cardiomyocytes (CMs) from the cell bank of the Chinese Academy of Science. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Lonza) with 10% foetal bovine serum (FBS; Gibco), 100 U/mL penicillin (Gibco) and 100 mg/ mL streptomycin (Gibco). All cells were maintained at 37°C in 5% CO 2 incubator.
| Lentivirus construction, cell transfection and treatment
We purchased recombinant lentivirus targeting lnc000908 or EP4 Primary CMECs were pre-incubated with LV-908 for 48 hours and further infected with LV-EP4 for additional 48 hours.
| Immunofluorescence assay
We performed immunofluorescence staining of vascular endothelial-cadherin (VE-cadherin), CD31, vimentin and α-smooth muscle actin (α-SMA). Cells were seeded in chamber slides, fixed with 4%
formaldehyde and then blocked with 0.1% Triton X-100 (Sigma- 
| Fluorescence in situ hybridization (FISH) for lnc000908
Fibrotic (21 days after Iso treatment) and normal hearts were fixed in 4% formalin for 48 hours, and paraffin sections of 5 μm Kit and Cy3-labelled probe were purchased from RiboBio Co., Ltd.
| Statistical analysis
Data are expressed as the mean ± SD. All statistical analyses were performed with SPSS17.0 software. We used one-way ANOVA for multigroup comparison (>2 groups) and the Student's t test for twogroup comparison. Furthermore, we considered P < 0.05 as statistically significant.
| RE SULTS
| Identification of a cardiac microvascular endothelial-enriched lncRNA that was up-regulated in cardiac fibrosis
First, we made the cardiac fibrosis rat's model by injecting Iso for 1 week. After another 2 weeks, rats were killed, heart tissues (about 100 mg) were removed for total RNA extraction, and remnant Of these changed lncRNAs, the expression of lnc000908 was quite noticeable and increased about fourfold in the fibrotic heart.
Remarkably, FISH image revealed that the lnc000908 (red colour)
dominantly expressed in the endothelium (CD31 immunofluorescence
A, Fluorescence in situ hybridization (FISH) showed that lnc000908 (red) is dominantly expressed in the endothelium (CD31 immunofluorescence staining, green) of fibrotic heart (n = 3). Red, lnc000908; green, CD31; nucleus was stained blue with DAPI. B, QRT-PCR analysis of lnc000908 expression in primary CMs, CFs and CMECs. Each experiment was repeated at least for three times. Data are presented as means ± SD. **P < 0.01 vs CM staining, green colour) of fibrotic heart ( Figure 2A) ; to validate it, we cultured primary CMECs, CFs and CMs. As shown in Figure 2B , qRT-PCR revealed that the expression of lnc000908 in CMECs was the highest among the three kinds of cells. These findings suggested that lnc000908 is a CMEC-enriched lncRNA.
| Silencing lnc000908 reduced cardiac fibrosis by inhibiting EndMT
To elucidate the potential role of lnc000908 in cardiac fibrosis, we delivered the shRNA by lentivirus (lenti-U6-shRNA-GFP) through tail vein injection; the next day, all animals received Iso treatment for the cardiac fibrosis model. We assessed the lentiviral transfection efficiency by qRT-PCR analysis, and the results revealed that the lnc000908 expression was down-regulated by about 55% compared with the control virus (lenti-U6-scramble RNA-GFP; Figure 3A ). The heart H&E and Masson's staining revealed that silencing lnc000908 reduced CMs disarray, fibrous hyperplasia ( Figure 3B,D) , and the level of collagen I and III ( Figure 3C ) induced by Iso. Furthermore, correlation with amelioration of cardiac fibrosis, cardiac pump function (by echocardiography analysis on days 21; Figure 3E ), such as LVESd, LVEDd, EF and FS ( Figure 3F ), also improved.
Owing to the lnc000908 endothelial dominant expression in the heart, we hypothesized that the protective effects of silencing lnc000908 could be mediated by EndMT. As shown in Figure 4A ,B, Iso treatment down-regulated CD31 but increased the α-SMA expression in the cardiac microvascular endothelium, namely enhanced EndMT, but silencing lnc000908 reversed the EndMT process. In addition, the EndMT marker expression was established by the Western blot analysis ( Figure 4C ).
Likewise, in primary cultured CMECs, the lnc000908 knockdown also blocked TGF-β-induced EndMT and demonstrated by CD31, VE-cadherin, α-SMA and vimentin protein expression (immunofluorescence stain in Figure 5A and Western blot in Figure 5C ,D). In contrast, the lnc000908 overexpression by lentivirus directly increased the α-SMA and vimentin expression and decreased CD31 and VE-cadherin protein by immunofluorescence staining ( Figure 6A ) and Western blot ( Figure 6C,D) .
The knockdown or overexpression efficiency was assessed by 
| Lnc000908 promoted EndMT by inhibiting the EP4 receptor
We analysed the lnc000908 gene location to identify the molecular mechanism of lnc000908. The lnc000908 gene and Western blot analysis revealed that both the RNA and protein expression of EP4 were markedly reduced in the fibrotic hearts of Iso-treated rats but were up-regulated after the lnc000908 knockdown ( Figure 7A,B) . In CMECs, the EP4 expression was consistent with that in the in vivo experiment ( Figure 7C,D) . The lnc000908 overexpression in CMECs decreased the mRNA and protein levels of EP4 ( Figure 7A,B) . More importantly, the cooverexpression of lnc000908 and EP4 in CMECs reversed lnc000908-induced EndMT ( Figure 7) . Conversely, silencing lnc000908 inhibitory effects on EndMT were also blocked by AH-23848 (a selective EP4 antagonist). These findings revealed that lnc000908 was directly related to EP4 and could inhibit the EP4 expression to promote
EndMT in Iso-induced cardiac fibrosis.
F I G U R E 4 Lnc000908 knockdown attenuates cardiac EndMT in vivo.
Immunofluorescence assay (A, B) and Western blot analysis (C) of α-SMA and CD31 in heart tissues, n = 3-4. Magnification ×20. Red, α-SMA; green, CD31; nucleus were stained in blue with DAPI. Each experiment was repeated at least for three times. Data are presented as means ± SD. ##P < 0.01 vs ctrl; *P < 0.05, **P < 0.01 vs Iso + lenti-ctrl | 6363
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| D ISCUSS I ON
This study provided evidence that the lncRNA misexpression exists in the development of Iso-induced cardiac fibrosis in rats. We identified a novel lnc000908 especially up-regulated in the cardiac fibrogenesis. The lnc000908 knockdown reduced EndMT in vivo to improve cardiac fibrosis and heart function. In addition, the overexpression or knockdown of lnc000908 in vitro induced or suppressed
EndMT, whereas down-regulated or up-regulated the EP4 level, respectively. Of note, these pro-or anti-EndMT effects resulting from the lnc000908 intervention were reversed by the EP4 overexpression or EP4 antagonist AH-23848. Overall, the findings demonstrated that the profibrotic action of lnc000908 was mediated by the down-regulation of EP4, and lnc000908 inhibited the EP4 expression to promote EndMT to participate in cardiac fibrosis.
Cardiac fibrosis represents an adaptive response of the heart to various stress. After the injury, activated CFs produce and secrete soluble procollagen I and III, which are processed by metalloproteinases, cross-linked by lysyl oxidases and hydroxylases, and finally formed into dense fibres. 1 As the predominant matrix-producing cells in the fibrogenesis, 24 the proliferation of fibroblasts and its trans-differentiation into myofibroblasts have been comprehensively investigated.
Besides CFs, EndMT is a vital contributor to cardiac fibrosis and is increasingly emphasized. Endothelial cells underwent EndMT to directly expand the fibroblast pool by the loss of endothelial cell characteristics and gain of mesenchymal cell properties. 3 In addition, diverse
ng/mL). AH-23848 (AH, a selective EP4 antagonist) was administrated 4 h after TGF-β exposure. Magnification ×40. CD31 and VEcadherin, green; α-SMA and Vimentin, red; nucleus were stained in blue with DAPI. B, Transfection efficiency was assessed by qRT-PCR of lnc000908 expression, n = 4. C and D, Western blot analysis of EndMT markers, n = 5. Each experiment was repeated at least for three times. Data are presented as means ± SD. *P < 0.05, **P < 0.01 vs ctrl; ^P < 0.05, ^^P < 0.01 vs TGF-β + si-ctrl; +P < 0.05, ++P < 0.01 vs TGF-β + si-908 however, all these lncRNAs are studied in CFs. To date, no evidence of lncRNA in cardiac EndMT has been reported.
In this study, lnc000908 is markedly up-regulated in fibrotic heart and mostly expressed in cardiac vascular endothelial cells.
In addition, qRT-PCR revealed that the lnc000908 expression was increased in primary TGF-β-treated CMECs. We then over- EndMT, but not fibroblasts, to aggravate cardiac fibrosis and cardiac dysfunction.
EP4 is the most extensively distributed PGE2 receptor subtype in the heart 8 and has been shown to play an antifibrotic role. 11, 12 Remarkably, the coexpression analysis revealed that the predicted target gene EP4 was closely located with lnc000908, implying that there might be a correlation between them. Our findings revealed that the mRNA and protein expression of EP4 was lowered in the fibrotic heart and TGF-β-treated primary CMECs. In addition, the lnc000908 knockdown increased, but the forced expression of lnc000908 decreased the mRNA and protein levels of EP4 in vitro, suggesting that EP4 was the direct downstream target gene of lnc000908. In this study, we noticed that the regulation of lnc000908 on EndMT was accompanied by the opposite change of the EP4 level. We further found that the improvement in EndMT resulted from the lnc000908 knockdown was abolished by pharmacological blocking of EP4 with AH-23848. Likewise, the lentiviral overexpression of EP4 also mitigated the increased EndMT caused by the forced expression of lnc000908. Our findings elucidated that EP4 mediates the EndMT regulation of lnc000908 in cardiac fibrosis.
Overall, these findings strengthen our hypothesis that lnc000908
reduces the EP4 expression to promote EndMT, thereby facilitating the progress of cardiac fibrosis.
LncRNAs affect almost every stage of the protein-coding gene expression through epigenetic modification, transcriptional regulation and post-transcriptional processing. 38, 39 Some lncRNAs have been reported as competing endogenous RNA (ceRNA) to regulate cardiac fibrosis at the post-translational level; for example, lncRNA H19 functions as ceRNA to mediate the CTGF expression by sponging miR-455 in cardiac fibrosis. 40 A study reported that lncRNA PFL contributes to cardiac fibrosis by acting as a ceRNA of let-7d. 37 Some lncRNAs bind to the chromatin modifier complex or transcription factors to mediate gene activation or repression. 41 Wang et al 42 unveiled that lncRNA Chaer is essential for cardiac hypertrophy progress by directly interfering with PRC2 to genomic loci, thereby inhibiting histone H3 lysine 27 methylation at the promoter regions of genes. Among all lncRNAs, large intergenic RNAs (lincRNAs) exhibit a potent capability to recruit histone modifier enzymes 43 and have been correlated with chromatin modifier complexes like PRC2. 44 As lnc000908 is a lincRNA and affects both RNA and protein levels of EP4, we assume that the EP4 regulation probably occurs at the transcriptional stage or even before. Perhaps, lnc000908 might regulate transcription factors or methylation and histone modification to repress EP4 transcription and, thus, promote EndMT to result in cardiac fibrosis. As our current data cannot answer how lnc000908 precisely inhibits the EP4 expression, comprehensive studies are warranted to elucidate the underlying mechanism in our future work.
Few lncRNAs are highly conserved across species compared with protein-coding genes, 45 and we failed to find the human homologous sequences of lnc000908. Despite sequence conservation, it also contains the conservation of structure, function and expression from syntenic loci. 45, 46 We will further detect lnc000908 expression in human hearts.
| CON CLUS IONS
This study elucidates that lnc000908 is a crucial mediator in the rat model of cardiac fibrosis. In addition, the inhibition of lnc000908
ameliorates cardiac fibrosis and heart function by up-regulating the EP4 level to hinder the EndMT process. Overall, our findings provide evidence that lncRNA might be a new antifibrotic target in the therapy of cardiac fibrosis.
